Cilostazol

Drug Profile

Cilostazol

Alternative Names: OPC-13013; OPC-21; Pletaal; Pletal

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Otsuka Pharmaceutical; Pfizer
  • Class Antiplatelets; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Intermittent claudication; Stroke
  • Phase III Angina pectoris
  • Discontinued Coronary artery restenosis

Most Recent Events

  • 01 Jan 2016 Otsuka Pharmaceuticals completes the phase III STELLA_Ext trial for Vasospastic Angina in South Korea (NCT02094469)
  • 01 Sep 2015 Otsuka Pharmaceutical initiates enrolment in the CiloMecT trial in Healthy volunteers (Adjunctive therapy) in Germany (NCT02554721)
  • 19 Sep 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top